Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study

Compared with Copaxone injection, treatment with oral Gilenya significantly reduced the annualized relapse rate in patients with relapsing remitting multiple sclerosis.

Source link

Related posts

Dissecting α-synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis


When Crisis Strikes, Don’t Eat All The Chocolate


Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World